Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELATIVE: Elafibranor in Primary Biliary Cholangitis
NCT04526665Phase 3Active, not recruiting
- Sponsor
- Ipsen
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Started Sep 2020; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04526665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04526665.